In private meetings, White House officials are working to win support from major pharmaceutical companies for a drug pricing bill, according to people familiar with the discussions. STAT+ reported that the White House drafted legislative text and is sharing it with more than a dozen large pharma firms, with the draft closely reflecting the administration’s voluntary deal framework. One policy lever under discussion would let drugs purchased in cash count toward a patient’s deductible. For biopharma, the direction of the legislative package is consequential for pricing mechanics, reimbursement strategy, and how companies forecast net revenue under negotiated frameworks. The next market signal will be which companies back the bill and how quickly companies can translate these policy details into operational planning.